Michael Gerg

This inventor holds 27 USPTO granted patents and 18 published patent applications, plus 5 CIPO patents and 20 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Roche Diagnostics Operations, Inc., Hoffmann-La Roche Inc., Roche Diagnostics Gmbh. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Gerg. Retrieved from https://idiyas.com/inventor/michael-gerg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 18)

% Patents Active = 70.4

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 20 (Patent Applications = 31)

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 23(Granted Patents)

Company Filing History:

13 out of 1,700

Roche Diagnostics Operations, Inc.

patents

11 out of 5,026

Hoffmann-La Roche Inc.

patents

2 out of 488

Roche Diagnostics Gmbh

patents

4. 1 out of 646

Roche Molecular Systems, Inc.

patents

5. 1 out of 548

Ventana Medical Systems, Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Binding Agents

Assays

PIVKA

Targeted Delivery

Polypeptides

Vitamin D Measurement

HER3 Antibodies

Insulin-like Growth Factor

Cross-linking Agents

Polynucleotide Complexes

Fusion Polypeptides

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760089 - SARS-COV-2 NUCLEOCAPSID ANTIBODIES (2026-10-13),

2. 12673999 - ANTI-CSF-IR ANTIBODY (2026-07-07),

3. 12559573 - Biotin-specific monoclonal antibody and use thereof (2026-02-24),

4. 12360108 - Biotin-specific monoclonal antibody and use thereof (2025-07-15),

5. 12351647 - Binding agent and assay for PIVKA (2025-07-08),

6. 12158466 - Method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto (2024-12-03),

7. 12025613 - Biotin-specific monoclonal antibody and use thereof (2024-07-02),

8. 11618790 - Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery (2023-04-04),

9. 11466098 - Binding agent and assay for PIVKA (2022-10-11),

10. 11415576 - Method for measurement of vitamin D (2022-08-16),

11. 10982007 - Detection of a posttranslationally modified polypeptide by a bivalent binding agent (2021-04-20),

12. 10808038 - HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2 (2020-10-20),

13. 10647765 - Amino acid sequence presenting fusion polypeptide and its use (2020-05-12),

14. 10626177 - HER3 antigen binding proteins binding to the beta-hairpin of HER3 (2020-04-21),

15. 10564151 - Method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto (2020-02-18),

Title: Michael Gerg: Pioneering Innovations in Munich.

Introduction:

Michael Gerg, a visionary inventor based in Munich, Germany, is renowned for his remarkable contributions to the world of inventions. With a total of 21 patents to his name, Gerg's inventive spirit and commitment to technological advancement have solidified his position as a true pioneer in the field.

Latest Patents:

1. Biotin-specific monoclonal antibody and use thereof: Gerg's groundbreaking invention revolves around a monoclonal antibody capable of binding to biotin. This antibody plays a crucial role in measuring analytes in samples using a (strept)avidin/biotin pair for specific binding.

2. Polypeptide-polynucleotide-complex for targeted effector moiety delivery: Another innovative creation by Gerg is a therapeutic polypeptide-polynucleotide-complex designed for targeted delivery of an effector moiety. This complex remains resistant to degradation in vivo and binds specifically to target compounds, tissues, or organs.

Career Highlights:

Throughout his career, Michael Gerg has made significant contributions to renowned companies such as Hoffmann-La Roche Inc. and Roche Diagnostics Operations, Inc. His innovative solutions and inventive mindset have left a lasting impact on the companies he has been associated with, shaping the landscape of innovation within these organizations.

Collaborations:

Gerg's collaborative efforts with industry experts such as Michael Schraeml and Christian Scholz have further enriched his innovative journey. By working alongside talented individuals, Gerg has been able to push the boundaries of traditional thinking and bring revolutionary ideas to fruition.

Conclusion:

In conclusion, Michael Gerg's relentless pursuit of innovation and his commitment to creating a better future through technology make him a true pioneer in the world of inventions. His remarkable contributions continue to inspire the next generation of inventors and shape the landscape of innovation for years to come.

Profile summary based on public USPTO records.